文献速递血管炎

巨细胞动脉炎与ANCA相关血管炎患者肺炎住院风险

Risk of hospitalization with pneumonia in patients with giant cell arteritis and anti-neutrophil cytoplasmic antibody associated vasculitis.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

基于丹麦全国患者登记的队列研究显示,巨细胞动脉炎(GCA)和ANCA相关血管炎(AAV)患者肺炎住院(HP)累积发生率及与匹配对照的风险差均升高,合并症和近期免疫抑制治疗与HP风险升高相关。

要点

  • GCA患者5年HP累积发生率为17.6%,较匹配对照风险差为5.3%。
  • AAV患者5年HP累积发生率为28.3%,较匹配对照风险差为20.4%。
  • 合并症和近期免疫抑制治疗与HP风险升高相关。

核心结论

  • GCA或AAV患者与匹配对照相比肺炎住院风险升高。
  • 合并症和近期免疫抑制治疗与HP风险升高相关,提示需要针对性预防策略。

研究设计与样本

  • 基于丹麦国家患者登记的人群队列研究,纳入2000至2021年诊断的GCA和AAV患者,按性别和出生年1:10匹配对照。
  • 采用伪观察法评估1年、2年和5年累积发生率比例(CIP)和风险差(RD),并进行巢式病例对照(NCC)分析评估影响HP风险的变量。

主要发现

  • 9307例GCA患者HP的CIP在1年、2年、5年分别为6.0%(5.5-6.5)、9.4%(8.8-10.0)、17.6%(16.8-18.4)。
  • 2401例AAV患者HP的CIP在1年、2年、5年分别为12.6%(11.2-13.9)、17.9%(16.3-19.5)、28.3%(26.4-30.3)。
  • NCC分析发现合并症和免疫抑制治疗与HP风险升高相关。

临床怎么用

  • GCA和AAV患者肺炎住院风险较匹配对照升高,合并症和近期免疫抑制治疗与风险升高相关,原文提出需要针对性预防策略。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aimed to assess the risk of hospitalization with pneumonia (HP) among patients with GCA and ANCA associated vasculitis (AAV). METHODS: This population-based cohort study identified patients with GCA and AAV diagnosed between 2000 and 2021 using the Danish National Patient Registry. Patients were matched 1:10 with controls on sex and year of birth. Using the pseudo-observation method we evaluated the cumulative incidence proportion (CIP) and risk difference (RD) after one, two and five years. Furthermore, a nested-case control (NCC) analysis was carried out to assess variables affecting the risk of HP. RESULTS: The CIP of HP for 9307 patients with GCA was 6.0% (5.5-6.5), 9.4% (8.8-10.0) and 17.6% (16.8-18.4) after one, two and five years. The RD compared with 92 806 matched controls was 3.0% (2.6-3.5), 3.8% (3.2-4.4), to 5.3% (4.5-6.1). For 2401 patients with AAV, the CIP of HP was 12.6% (11.2-13.9), 17.9% (16.3-19.5) and 28.3% (26.4-30.3) after one, two and five years. Compared with 24 013 matched controls, the RD was 10.1% (8.8-11.5), 14.8% (12.3-15.4) and 20.4% (17.9-21.8). The NCC found comorbidities and immunosuppressive treatment to be associated with higher risk of HP. CONCLUSION: Patients with GCA or AAV had increased risk of HP compared with matched controls. Comorbidities and recent immunosuppressive treatment were associated with higher risk of HP, highlighting the need for focused preventive strategies.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Sørensen MER, Cordtz R, Duch KS, et al. Risk of hospitalization with pneumonia in patients with giant cell arteritis and anti-neutrophil cytoplasmic antibody associated vasculitis. Rheumatology (Oxford). 2026. PMID: 41160483. doi:10.1093/rheumatology/keaf564

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。